ACAD
ACADIA PHARMACEUTICALS INC
$21.10
-1.03%
$3.6B
No data for this timeframe.
Vol
Market Cap$3.6B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders9 funds
Inst. Value$635.3M
Inst. Activity4 buys / 0 sells
Insider Activity0B / 12S
Insider Net $-$957.1K
SEC Reports5
Recent Activity
May 6, 2026
SEC
Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (
8-K — Impact 6/10
May 6, 2026
earnings_calendar
ACAD Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
SEC
Two ACAD insiders (CFO and principal accounting officer) sold small open-market positions totaling ~$105K on May 4, 2026
CLUSTER — Impact 2/10
May 4, 2026
Insider
Schneyer Mark C. sold 3,506 shares
EVP, CHIEF FINANCIAL OFFICER @ $21.79 ($76.4K)
May 4, 2026
Insider
Kihara James sold 1,332 shares
PRINCIPAL ACCOUNTING OFFICER @ $21.79 ($29.0K)
May 1, 2026
Insider
Schneyer Mark C. sold 6,815 shares
EVP, CHIEF FINANCIAL OFFICER @ $0.00 ($0.00)
Mar 27, 2026
SEC
Multiple C-suite executives at Acadia Pharmaceuticals, including the CEO, CFO, and other senior officers, conducted open
CLUSTER — Impact 4/10
Inst.
NORGES BANK — NEW
1,507,527 shares ($40.3M)
Price Targets
$31.65
+50.0% upside
Strong Buy
Current $21.10
Low $17.00
Median $32.00
High $45.00
20 analysts
$17.00
$45.00
Analyst Ratings
7Strong Buy
14Buy
5Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 8, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | B of A Securities | UPGRADE | Neutral → Buy |
| Mar 4, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Feb 26, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| Feb 26, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.04 ▼ -66.2% | $-0.05 — $0.12 | -76% YoY | 11 |
| Next Q | $0.12 ▲ +1.9% | $0.08 — $0.15 | -71% YoY | 11 |
| Current FY | $0.40 ▼ -18.0% | $0.23 — $0.74 | -52% YoY | 12 |
| Next FY | $0.89 ▼ -5.9% | $0.50 — $1.70 | 125% YoY | 11 |
Latest Reports
BEARISH
8-K
6/10
Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (
May 6, 2026
NEUTRAL
CLUSTER
2/10
Two ACAD insiders (CFO and principal accounting officer) sold small open-market positions totaling ~$105K on May 4, 2026
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $404.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $40.9M | DOUBLED |
| NORGES BANK | $40.3M | NEW |
| BANK OF AMERICA CORP | $32.6M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $31.3M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 4, 2026 | Schneyer Mark | SELL | $76.4K |
| May 4, 2026 | Kihara James | SELL | $29.0K |
| May 1, 2026 | Schneyer Mark | M | $0.00 |
| May 1, 2026 | Schneyer Mark | M | $0.00 |
| May 1, 2026 | Kihara James | M | $0.00 |
9 institutional holders with $635.3M total value (23,785,084 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, NORGES. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 15,153,957 | $404.8M | 63.7% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,532,596 | $40.9M | 6.4% | DOUBLED +204.2% |
| 3 | NORGES BANK | 1,507,527 | $40.3M | 6.3% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 1,221,445 | $32.6M | 5.1% | ADD +37.6% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,172,317 | $31.3M | 4.9% | NEW |
| 6 | MORGAN STANLEY | 1,141,974 | $30.5M | 4.8% | TRIM -71.1% |
| 7 | TWO SIGMA INVESTMENTS, LP | 1,119,117 | $29.9M | 4.7% | ADD +68.1% |
| 8 | FMR LLC | 726,963 | $19.4M | 3.1% | DOUBLED +293.1% |
| 9 | WELLS FARGO & COMPANY/MN | 209,188 | $5.6M | 0.9% | ADD +38.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 1,507,527 | — | $40.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 887,848 | 1,221,445 | +37.6% | $32.6M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 665,891 | 1,119,117 | +68.1% | $29.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 150,803 | 209,188 | +38.7% | $5.6M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 4,111,247 | 1,188,406 | -71.1% | $25.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 483,098 | 665,891 | +37.8% | $14.2M | 2025-Q3 |
| FMR LLC | DOUBLED | 169,362 | 665,810 | +293.1% | $14.2M | 2025-Q3 |
| NORGES BANK | EXIT | 1,468,647 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 1,468,647 | — | $31.7M | 2025-Q2 |
| UBS Group AG | TRIM | 1,056,850 | 736,223 | -30.3% | $15.9M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 816,656 | 483,098 | -40.8% | $10.4M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 199,745 | 138,694 | -30.6% | $3.0M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 7,297,049 | 4,680,183 | -35.9% | $77.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,243,442 | 816,656 | -34.3% | $13.6M | 2025-Q1 |
| FMR LLC | ADD | 138,025 | 174,251 | +26.2% | $2.9M | 2025-Q1 |
| NORGES BANK | EXIT | 1,392,618 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 1,675,854 | 7,297,049 | +335.4% | $133.9M | 2024-Q4 |
| UBS Group AG | DOUBLED | 604,152 | 1,241,275 | +105.5% | $22.8M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 403,200 | 1,226,533 | +204.2% | $22.5M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 278,162 | 499,365 | +79.5% | $9.2M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 2,391,105 | 1,675,854 | -29.9% | $25.8M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,271,135 | — | $19.6M | 2024-Q3 |
7 unique insiders with 12 transactions. Net insider value: -$957.1K ($0.00 bought, $957.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 4, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 3,506 | $21.79 | $76.4K |
| May 4, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | SELL | 1,332 | $21.79 | $29.0K |
| May 1, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M | 6,815 | $0.00 | $0.00 |
| May 1, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M | 6,815 | $0.00 | $0.00 |
| May 1, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M | 2,596 | $0.00 | $0.00 |
| May 1, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M | 2,596 | $0.00 | $0.00 |
| Apr 7, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | SELL | 1,030 | $22.20 | $22.9K |
| Apr 7, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 2,709 | $22.20 | $60.1K |
| Apr 5, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M | 5,276 | $0.00 | $0.00 |
| Apr 5, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M | 5,276 | $0.00 | $0.00 |
| Apr 5, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M | 2,010 | $0.00 | $0.00 |
| Apr 5, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M | 2,010 | $0.00 | $0.00 |
| Mar 26, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | SELL | 1,097 | $21.65 | $23.8K |
| Mar 26, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 3,171 | $21.65 | $68.7K |
| Mar 25, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | SELL | 833 | $21.47 | $17.9K |
| Mar 25, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M | 2,142 | $0.00 | $0.00 |
| Mar 25, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M | 2,142 | $0.00 | $0.00 |
| Mar 25, 2026 | Owen Adams Catherine | Chief Executive Officer | SELL | 11,641 | $21.47 | $249.9K |
| Mar 25, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | SELL | 3,844 | $21.47 | $82.5K |
| Mar 25, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | SELL | 3,435 | $21.47 | $73.7K |
| Mar 25, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M | 6,178 | $0.00 | $0.00 |
| Mar 25, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 4,177 | $21.47 | $89.7K |
| Mar 25, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M | 6,178 | $0.00 | $0.00 |
| Mar 24, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M | 1,627 | $0.00 | $0.00 |
| Mar 24, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | M | 1,627 | $0.00 | $0.00 |
| Mar 24, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M | 8,138 | $0.00 | $0.00 |
| Mar 24, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | M | 7,515 | $0.00 | $0.00 |
| Mar 24, 2026 | Owen Adams Catherine | Chief Executive Officer | M | 23,509 | $0.00 | $0.00 |
| Mar 24, 2026 | Owen Adams Catherine | Chief Executive Officer | M | 23,509 | $0.00 | $0.00 |
| Mar 24, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | M | 6,715 | $0.00 | $0.00 |
| Mar 24, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | M | 6,715 | $0.00 | $0.00 |
| Mar 24, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | M | 7,515 | $0.00 | $0.00 |
| Mar 24, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | M | 8,138 | $0.00 | $0.00 |
| Mar 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | A | 90,691 | $0.00 | $0.00 |
| Mar 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | A | 26,382 | $0.00 | $0.00 |
| Mar 6, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | A | 21,766 | $0.00 | $0.00 |
| Mar 6, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | A | 6,332 | $0.00 | $0.00 |
| Mar 6, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | A | 90,691 | $0.00 | $0.00 |
| Mar 6, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | A | 26,382 | $0.00 | $0.00 |
| Mar 6, 2026 | Garner Thomas | EVP, Chief Commercial Officer | A | 97,947 | $0.00 | $0.00 |
| Mar 6, 2026 | Garner Thomas | EVP, Chief Commercial Officer | A | 28,493 | $0.00 | $0.00 |
| Mar 6, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | A | 101,574 | $0.00 | $0.00 |
| Mar 6, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | A | 29,548 | $0.00 | $0.00 |
| Mar 6, 2026 | Owen Adams Catherine | Chief Executive Officer | A | 263,005 | $0.00 | $0.00 |
| Mar 6, 2026 | Owen Adams Catherine | Chief Executive Officer | A | 76,509 | $0.00 | $0.00 |
| Mar 3, 2026 | Poole Jonathan | Director | A | 4,218 | $0.00 | $0.00 |
| Mar 3, 2026 | Poole Jonathan | Director | A | 7,482 | $0.00 | $0.00 |
| Feb 9, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | SELL | 6,950 | $23.38 | $162.5K |
| Feb 6, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | M | 12,944 | $0.00 | $0.00 |
| Feb 6, 2026 | Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | M | 12,944 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.6/10.
BEARISH
8-K
6/10
Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) an
May 6, 2026
NEUTRAL
CLUSTER
2/10
Two ACAD insiders (CFO and principal accounting officer) sold small open-market positions totaling ~
May 5, 2026
NEUTRAL
CLUSTER
4/10
Multiple C-suite executives at Acadia Pharmaceuticals, including the CEO, CFO, and other senior offi
Mar 27, 2026
NEUTRAL
8-K
3/10
Acadia Pharmaceuticals appointed Jonathan M. Poole to its board of directors and the Audit Committee
Mar 5, 2026
BULLISH
8-K
8/10
Acadia Pharmaceuticals reported strong fourth quarter and full year 2025 results, with GAAP revenue
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (78% buy). Based on 27 analysts: 7 strong buy, 14 buy, 5 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$31.65 mean target
+50.0% upside
Strong Buy (1.76)
$17.00 Low
$45.00 High
| Metric | Value |
|---|---|
| Current Price | $21.10 |
| Target Low | $17.00 |
| Target Mean | $31.65 |
| Target Median | $32.00 |
| Target High | $45.00 |
| # Analysts | 20 |
| Recommendation | Strong Buy (1.76) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.04 | $-0.05 | $0.12 | -76.2% | -66.2% | 1↑ 5↓ | $0.3B | 11.6% | 11 |
| Next Q 2026-09-30 |
$0.12 | $0.08 | $0.15 | -70.7% | +1.9% | 4↑ 2↓ | $0.3B | 16.8% | 11 |
| Current FY 2026-12-31 |
$0.40 | $0.23 | $0.74 | -52.1% | -18.0% | 1↑ 8↓ | $1.2B | 15.8% | 12 |
| Next FY 2027-12-31 |
$0.89 | $0.50 | $1.70 | 124.8% | -5.9% | 1↑ 5↓ | $1.4B | 11.9% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.038 | |
| 7d ago | $0.110 | -0.072 |
| 30d ago | $0.113 | -0.075 |
| 60d ago | $0.111 | -0.073 |
| 90d ago | $0.197 | -0.159 |
12 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 8, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | B of A Securities | UPGRADE | Neutral | Buy |
| Mar 4, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 26, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Feb 26, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Feb 23, 2026 | Mizuho | UPGRADE | Neutral | Outperform |
| Feb 6, 2026 | Oppenheimer | MAINTAIN | Perform | Perform |
| Feb 3, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 3, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Feb 3, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 6, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | UBS | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 11, 2025 | Stifel | MAINTAIN | Hold | Hold |
| Dec 2, 2025 | Mizuho | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 7 | 14 | 5 | 1 | 0 | 78% | |
| Apr 1, 2026 | 7 | 14 | 5 | 1 | 0 | 78% | |
| Mar 1, 2026 | 6 | 14 | 6 | 1 | 0 | 74% | |
| Feb 1, 2026 | 5 | 13 | 7 | 1 | 0 | 69% | |
| Jan 1, 2026 | 5 | 13 | 7 | 1 | 0 | 69% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 6, 2026
earnings_calendar
ACAD Q1 2026 Earnings Scheduled — 2026-05-06
Apr 24, 2026
short_interest
FTD: ACAD — 25,749 shares ($0.6M) failed to deliver
Settlement: 20260424, Price: $22.11, FTD Value: $569,310.39, ACADIA PHARMACEUTICALS INC
Apr 17, 2026
short_volume
Short Volume: ACAD — 56.9% short (0.4M / 0.8M)
Short: 444,240 | Exempt: 300 | TRF Vol: 780,943 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
short_volume
Short Volume: ACAD — 56.7% short (0.3M / 0.6M)
Short: 349,618 | Exempt: 2,815 | TRF Vol: 616,870 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: ACAD — 62.6% short (0.4M / 0.6M)
Short: 375,376 | Exempt: 4,488 | TRF Vol: 599,320 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: ACAD — 55.8% short (0.3M / 0.6M)
Short: 316,174 | Exempt: 1,915 | TRF Vol: 566,599 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
Mar 25, 2026
short_volume
Short Volume: ACAD — 57.2% short (0.4M / 0.7M)
Short: 418,272 | Exempt: 6,036 | TRF Vol: 731,227 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Feb 25, 2026
earnings_calendar
ACAD Q4 2025 Earnings After Market Close — 2026-02-25
Feb 6, 2026
short_interest
FTD: ACAD — 33,067 shares ($0.8M) failed to deliver
Settlement: 20260206, Price: $23.46, FTD Value: $775,751.82, ACADIA PHARMACEUTICALS INC
Aug 5, 2025
FDA
DAYBUE
Supplemental Approval — Labeling — TROFINETIDE — SOLUTION — ORAL